ArticleMediterranean journal of rheumatology2022
Assessment of Serum Resistin and Plasma Calprotectin Levels as Biomarkers of Inflammation in Patients with Familial Mediterranean Fever Disease.
Article in Mediterranean journal of rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Serum resistin levels in pediatric familial Mediterranean fever: Potential biomarker for inflammatory activity.World journal of clinical pediatrics · 2025Article
- The role of NETosis in breast cancer: mechanistic insights and biomarker potential.Breast cancer research : BCR · 2025Review
- Article
- Inflammatory biomarker analysis confirms reduced disease severity in heterozygous patients with familial Mediterranean fever.RMD open · 2024Article
- A plasmonic biosensor pre-diagnostic tool for Familial Mediterranean Fever.Nature communications · 2024Article
- Exploring S100A8/A9, neopterin, and MMP3 in familial Mediterranean fever.Clinical and experimental immunology · 2024Article
- Role of serum calprotectin in identifying familial Mediterranean fever attacks.Irish journal of medical science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: While several inflammatory markers are known to increase in familial Mediterranean fever (FMF) disease cases, the need remains for diagnostic tests specific for FMF that monitor inflammatory activity. We aimed to investigate resistin and calprotectin levels during both attack and attack-free periods of FMF disease and evaluate their use as novel biomarkers of inflammation in patients with FMF. Materials and Methods: This cross-sectional study included 68 male patients diagnosed with FMF and 20 healthy individuals as controls. Blood samples were obtained from the patients in attack-free periods (at least 15 days after the last attack) and attack periods (in the first 24 hours). Serum resistin and plasma calprotectin levels was measured by ELISA method. Results: Resistin and calprotectin levels were significantly higher in patients during both attack (p =0.001, p <0.001) and attack-free periods (p =0.017, p =0.01) compared to the control group. Logistic regression analysis indicated that resistin levels were predictive for the diagnosis of FMF disease (OR: 1.21; 95% CI: 1.04-1.42; p =0.016). Resistin and calprotectin levels significantly correlated with C-reactive protein, erythrocyte sedimentation rate, fibrinogen, and white blood cells (0.301≤ r ≤ 0.505, p <0.05). Conclusion: Resistin and calprotectin levels were significantly higher in patients than controls, and resistin was predictive for monitoring inflammatory activity in patients with FMF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.